

# **CTSA Program Webinar**

July 24, 2024



# **Agenda**

TIME	TOPIC	PRESENTERS
2:00 PM ET	Welcome	Lauren Fitzharris, M.P.H., P.M.P. CCOS
2:01 – 2:10 PM	NCATS/CTSA Updates	Michael Kurilla, M.D., Ph.D. NCATS
2:10 – 2:15 PM	CCOS Updates	Lauren Fitzharris M.P.H., P.M.P. CCOS
2:15 – 2:40 PM	Office of Research on Women's Health	Vivian Ota Wang, Ph.D., FACMG NIH/ORWH
2:40 – 3:00 PM	Comparative Genomics Resources for the CTSAs	Terence Murphy, Ph.D. NIH
3:00 PM	Adjourn	





# **NCATS/CTSA Program Updates**

Michael Kurilla, MD, PhD


Director, Division of Clinical Innovation NCATS

July 24, 2024




# FY 2025 NCATS President's Budget

#### **Funding History**



#### **NCATS** Budget by Activities







# NCATS Strategic Plan Launch

NCATS Director Joni Rutter is hosting a series of roundtables with the CTSA and other NCATS communities to launch the new strategic plan.



#### CTSA Roundtables:

- CAB Members: Oct. 2nd, 3:00 PM ET
- Pls and Deans: Oct. 4th, 1:00 PM

Stay tuned for more details

# Notice of Clarification to PAR-21-293 Pilot Module

- Released June 26, 2024 (<u>NOT-TR-24-029</u>)
- **Specific** changes in Element D: Clinical and Translational Science Resources and Pilots, Module D2: Clinical and Translational (CTS) Pilot in <u>PAR-21-293:</u>
- Clinical and Translational Science Pilot Module
  - Include costs for the review, tracking, management, and overall administration of the Module as well as the Pilot projects:
    - Number of Pilot Projects: A minimum of four and a maximum of eight active Pilot projects, per budget period.
    - Budgets: Must be between \$25,000 and \$50,000, direct costs.
    - Project Period: Cannot exceed 12 months.
    - Recipient must ensure that the active number of pilot projects does not exceed the maximum number of pilot projects proposed to be supported per budget year in the competing application.



Please direct all inquiries to: <a href="mailto:CTSANOFOQuestions@mail.nih.gov">CTSANOFOQuestions@mail.nih.gov</a>



Online Application Period: Sep 1, 2024 - Nov 21, 2024

- Extramural Loan Repayment Program for Clinical Researchers (LRP-CR) (NOT-OD-24-134)
- Extramural Loan Repayment Program for Pediatric Research (LRP-PR) (NOT-OD-24-135)
- Extramural Loan Repayment Program for Health Disparities Research (LRP-HDR) (NOT-OD-24-136)
- Extramural Clinical Research Loan Repayment Program for Individuals from Disadvantaged Backgrounds (LRP-IDB) (NOT-OD-24-138)
- <u>Extramural Loan Repayment Program for Contraception and Infertility Research (LRP-CIR)</u> (NOT-OD-24-139)
- Extramural Loan Repayment Program for Research in Emerging Areas Critical to Human Health (LRP-REACH) (NOT-OD-24-137)
  - REACH Priority Statements for NCATS:
    - Data science and health informatics to provide clinical decision support of health care providers
    - Telehealth and mobile health research approaches to improve the health of under-served and under-represented populations





NCATS POC: Dr. David Wilde: wilded@mail.nih.gov

https://www.lrp.nih.gov/

## Summer & Fall 2024: 3 Integrated Efforts

**Learning Landscape Analysis** 

#### **Engage Community & Stakeholders**

Core team, working group, advisors


#### **Skills Mapping**

Team Science - roles & audiences Intro, intermed, advanced competencies

**Equity Mapping** - who needs access?

**Learner Journey** - where to deliver?

**Design Strategies Mapping** - how might we best address the needs & provide trainings, programs, train-the-trainers?



# **Curating & Adapting Existing Resources**

#### **Environmental/Market Scan**

What currently exists?

#### **Collaborate & Curate**

Link to & amplify existing tools

#### **Adapt for e-learning**

DEIA & Interprofessional learners

#### **Gap Analysis & Prioritization**

What's missing?

## **Creating New Resources**

Partner with SMEs to Co-design/develop
PHASTR Call for Proposals
Create New Trainings to meet needs & Open Access Portal



# **Vision** Real-world Data Training Hub for and by the community

To collaborate & leverage our RWD experience and resources to co-design, grow, and sustain a Real-world Data Training Hub that provides open access training resources for all individuals - in the CTSAs and beyond in order to elevate the quality of translational science and the value of real-world evidence for improving health and care.

Government **NCATS NIGMS** Community AIM-AHEAD **CTSAs** AllofUs **CTRs HBCUs Industry** Datasets **Platforms** Examples



# Creating New RWD Trainings

# Machine Learning Applications in Drug Discovery, Translational Research & Clinical Medicine



Instructor: Dave Sahner, MD Release Date: October 2024 This **foundational course** provides a comprehensive introductory exploration of topics in artificial intelligence, machine learning, and deep learning.

In addition to technical knowledge, this course emphasizes the importance of foundational principles for successful ML implementation and the transformative role of AI in medicine, drug discovery, and translational research, highlighting the challenges and opportunities in integrating AI into healthcare and biotechnology.



# NCATS RWD Training Hub Development

## **Available Now**

#### **Collaboration & Support**

Email aubri.hoffman@nih.gov

#### **NCATS Education Website**

Principles of Preclinical Translational Science Digital Badging Program

#### **Data Science Educational Enclave**

4 simulated & 60 public data sets

Researcher's Guide online textbook

Training tools, including RWD Glossary

>2000 knowledge objects and concept sets

#### **RWD Courses on AIM-AHEAD Connect**

5 ADATP courses on RWD infrastructure, Clinical Data Management, Translational Projects, etc. 13 additional open access courses on programming in R/Python, Al, health equity, etc.

## **Coming Soon**

#### **Good Algorithmic Practices courses**

Introduction to health AI/ML & best practices Advanced skills & innovations in health ML/DL

### **PHASTR Call for Proposals**

Collaboration & funding to co-develop other priority topics

### **RWD State-of-the-Learning Report**

Skills & Competencies Map
Training pathways and program recommendations

#### **NCATS RWD Training Hub**

Curated links to existing courses & data sets New courses, tutorials & templates Reports, recommendations & toolkits Workshops & webinars



# **Upcoming Dates to Remember**

Next CTSA Program Webinar
AUGUST IS CANCELLED
September 25, 2024; 2-3 PM ET. Register here.



# NGATS

COLLABORATE. INNOVATE. ACCELERATE.











# **CCOS Updates**

Lauren Fitzharris
CCOS



# Fall 2024 CTSA Program Meeting

Building CTSA Program Impact through Innovation, Collaboration and Equity

**DATE**: November 13-15<sup>th</sup>

**LOCATION**: Bethesda North Marriott

**Day 1**:

- TIN Meeting
- CTSA Administrators Meeting
- CTSA Steering Committee Meeting

Days 2 (full day) and 3 (half day):

CTSA Program Meeting

More details and online registration to come!

**Questions?** 

Contact FallMtg@ccos.ctsa.io



# 2024 Fall CTSA Program Agenda Topics

## Topics to be covered include:

- Primary Care Practice-Based Research Networks (PBRNs)
- PCORnet
- The Women's Health Initiative and DEI
- Translational Research to Translational Science
- Generative AI and Large Language Models in Translational

# 2024 Fall CTSA Program Meeting – DRAFT AGENDA

Day 2- Nov. 14		
Session	Timing (ET)	
Session 1: Welcome & Keynote	<b>8:30am</b> –9:45am	
Break	9:45am-10:00am	
Session 2: Collaborations with PBRNs	10:00am-11:30am	
Poster Presentations (Group A)	11:30am-12:15pm	
Lunch	12:15pm-1:45pm	
Session 3: CTSA Collaborations (PCORNet) / Innovations (TIN, ENACT, N3C)	1:45pm-3:15pm	
Break	3:15pm-3:30pm	
Poster Presentations (Group B)	3:30pm-4:15pm	
Session 4: Women's Health Initiative / DEIA	4:15pm- <b>5:45pm</b>	

Day 3- Nov. 15			
Session	Timing (ET)		
Session 5: TR to TS	<b>8:00am</b> -9:15am		
Break	9:30am-9:45am		
Session 6: Generative AI / LLM	9:45am-10:45am		
Break	10:45am-11am		
Session 7: NCATS Session	11:00am – 12:30pm		
Closing Session	12:30pm – <b>1:00pm</b>		

# Cycle XII: New CTSA Working Groups

- RWD Workforce Development Across the Translational Spectrum submitted by Dr. Melissa Haendel, UNC
  - WG Mailbox: <a href="mailbox">RWD.WG@ccos.ctsa.io</a>
  - WG Webpage: <u>RWD Workforce Development WG</u>
- Translational Impacts submitted by Dr. Kristi Holmes, Northwestern University and Dr. Emmanuel Tetteh, Washington University in St. Louis
  - WG Mailbox: <u>Translational.Impacts@ccos.ctsa.io</u>
  - WG Webpage: <u>Translational Impacts WG</u>
- Webpages will be updated soon with more details, e.g., meeting occurrence

Cycle XIII Opens September 1 – 30<sup>th</sup>



# **CCOS Website Account**

# **Getting Started**

Get step-by-step guidance on getting started including how to create a CCOS account and how to log in can be found here:

Getting Started Page

## Account Access Includes:

- Meeting Materials/Archives
- ➤ Collaborative Spaces
- **➤** Discussion Forums
- ➤ CTSA Hub Directory

Questions? Please email <a href="mailto:support@ccos.ctsa.io">support@ccos.ctsa.io</a>.

# Want to stay up to date on the CTSA Program?

Follow this link or scan the QR code to join the CCOS All Communications Email List to receive CTSA Program communications and updates:

http://eepurl.com/iw9nZA



Remember to add <a href="mailto:cos.ctsa.io">communications@ccos.ctsa.io</a> to your contacts list to prevent important CCOS emails from ending up in your spam folder!



Clinical and Translational Science Awards (CTSA) Program Webinar

July 24, 2024



Vivian OTA WANG, Ph.D., CGC, FACMG

Deputy Director

Office of Research on Women's Health

National Institutes of Health

# Why Sex and Gender Matter



NIH Office of Women's Health Research



Sex and Gender Equity in Research (SAGER) Guidelines




White House Women's Health Research Initiative



Implications and Next Steps



# Women Experience Health and Disease Differently



# DOES SEX MATTER?

"[Sex]...is an important basic human variable that should be considered when designing and analyzing the results of studies in all areas and at all levels of biomedical and health related research

# Before 1993,

most testing done in clinical trials and diagnostic and device development was conducted on men.



Cardiovascular disease is the #1 killer of WOMEN in the US, yet only 1/3 of the participants in clinical trials are female.

TRIAL SUBJECTS



#### Not until 2016

were female mice mandated to be included in research by NIH.





78% of Americans with autoimmune disease are women-it is estimated that

## 50 million

people are afflicted.

## Male animals

outnumber females 5 to 1 in pharmacology studies—and 3.7 to 1 in physiology studies.



00000



Lung cancer is the #1 cause of cancer death in women.

More women die of lung cancer each year than from breast, ovarian and uterine cancers combined.

Non-smoking women are three times more likely than CANCER non-smoking men to get it.

## Twice

as many women as men suffer from depression in the U.S. It is the leading cause of disability in women.



Women are people suffering from

Alzheimer's disease

neuroscience research are male or of unreported gender.



of animal studies researching strokes used femalesalthough these conditions occur more often in women.

Fewer than 45% of animal studies of anxiety and depression use female lab animals, although these disorders are twice as common in women.



MALE STUDIES

**FEMALE STUDIES** 




While many brain disorders show substantial differences across gender, animal studies using only males outnumber studies that include females


5.5 to 1.


A woman's risk of developing Alzheimer's disease is almost



that of a man. and not just because women live longer.










NIH Policy and Guidelines on The Inclusion of Women and Minorities as Subjects in Clinical Research

The NIH Revitalization Act of 1993 (Public Law 103–43) directed NIH to ensure women and racial and ethnic minorities are appropriately represented in NIH-funded clinical research



#### Inclusion Across the Lifespan Policy

Section 2038(H) of the 21st
Century Cures Act requires
NIH to update guidelines
for the inclusion of women
and minorities in clinical
research to reflect
individuals of all ages
included in NIH clinical
research


Requires




# Expansion of The NIH Inclusion Policy and Guidelines


A provision was made requiring that applicable NIH-defined Phase III clinical trials report results of valid analysis by sex/gender, race, and ethnicity on ClinicalTrials.gov.

# Society, Policy, and Influence Human Health



Greene, CS, et al, (2015) *Nature Genetics*, 47, 569-576. https://doi.org/10.1038/ng.3259 https://visual.ly/community/interactive-graphic/health/network-graph-human-diseases





14 Uveitis

15 Choroid diseases

12 Spontaneous abortion

# Women and Men May Follow Different Paths to Disease and Health



# Biopsychosocial Interactions of Biology and Culture

#### **Environment**

#### Culture

Sex & gender assumptions affect research & clinical practice

#### Organism


Differences in Disease Manifestation

#### **System**


All systems, not just reproductive system

#### Cell

Genes, Intracellular processes








Gendered assumptions affect the *nature*, *interactions*, and *practices* of research

- Researchers
- Research participants,
  - Communities
  - Institutions


All levels interact and simultaneously influence each other




# **Postmenopausal Women:**


At *Significantly Higher* Cardiovascular Disease Risk Than Premenopausal Women

Midlife:
Pivotal Time for
Chronic Disease
Onset Among
Women



CRITICAL: Address role of menopause in health of midlife women for preventing, diagnosing, and treating chronic disease(s)







# **Condition Type**

# Examples

Distinctly Female
Specific

- Endometriosis
- Cervical Cancer
- Menopause



**Disproportionately Impact Women** 

- Autoimmune Disease
- Osteoarthritis
- Chronic Pain



Present and Progress

Differently in Women

- Cardiovascular Disease
- Stroke
- Metabolic Disorders



# Menopause

Menopause is the first 12 months after a woman's last period

 Menopause is a "stress test" that may help predict later-life health concerns


Menopausal transition, perimenopause, typically between the ages of 45 and 55


Affects women differently

- Irregular periods, vaginal dryness
- Hot flashes, chills, night sweats
- Sleep problems and mood changes
- Weight gain and slowed metabolism
- Thinning hair and dry skin; loss of breast fullness



- Significantly impacts
  - Brain structure and functions
  - Connectivity, metabolic functioning during hormonal and chronological aging of the female brain








#### **Autoimmune Diseases** Women 75% **Brain & Nervous System Eye and Mouth** Multiple Sclerosis Sjogren's Syndrome Uveitis (eye) Men 25% **Thyroid** Lungs Grave's Disease/Hashimoto's Autoimmune **Thyroiditis** PulmonaryFibrosis Heart Autoimmune diseases **Disproportionately** Cardiomyopathy affect 7-8% of **Kidneys** Autoimmune Myocarditis Impacts Women population Lupus Juvenile Diabetes (23.5 million Glomerulonephritis Skin Americans) Pemphigus Scleroderma **Gastrointestinal** • 4X more women than Crohn's Disease men affected by Celiac Sprue **Blood** autoimmune diseases **Joints** Hemolytic Anemia Neutropenia Rheumatoid Arthritis Autoimmune Thrombocytopenic Purpura Pernicious anemia



### Cardiovascular Disease

- Women with myocardial infarction receive less guideline-based diagnosis and less-invasive treatment than men<sup>1</sup>
- Women with atrial fibrillation receive less anticoagulation treatment with warfarin (with greater risk for stroke than men)<sup>2</sup>

Women less likely to receive **Cardiopulmonary Resuscitation** (CPRP from EMTs at an



(¹ Regitz-Zagrosek V. Therapeutic implications of the gender-specific aspects of cardiovascular disease. Nat Rev Drug Discov 2006; 5: 425–438.

¹ Humphries KH et al. New-onset atrial fibrillation: sex differences in presentation, treatment, and outcome. Circulation 2001; 103: 2365–2370.

³ Rubenson Wahlin R, et al. Do male and female trauma patients receive the same prehospital care?: an observational follow-up study. BMC Emerg Med. 2016; 16: 6

Regitz-Zagrosek V. Sex and gender differences in health. EMBO Rep. 2012 Jul; 13(7): 596–603)



U.S. Department of Health and Human Services Centers for Disease Control and Prevention


About 20% of women report mistreatment while receiving maternity care

#### THE LANCET

Globally, cancer ranks in <u>Top 3</u>


<u>Causes</u> of Premature mortality

among women



People living with autoimmune diseases are women

# Gaps and Incomplete Knowledge




# Disaggregating Results by Sex Reveals Differences


Study produced novel findings due to disaggregating results by sex

**Aggregated Results** 

**Disaggregated Results** 

HIDING IN PLAIN SIGHT





McCullough, et al. Journal of Cerebral Blood Flow & Metabolism. 2005. DOI: 10.1038/sj.jcbfm.9600059

# Office of Research on Women's Health (ORWH) Mission

# **National Institutes of** Health (NIH) Vision



Sex and gender integrated into biomedical research



Every woman receives evidence-based care



Women in science careers reach their full potential



Include women and minority

groups in clinical research





Promote career advancement for women in biomedical careers





#### Collaboration is Key to Women's Health Research at NIH







NIH Institutes and Centers

**Partnership** 

Office of Research on Women's Health

Priority Setting

Driving synergistic research priorities

NIH-Wide Workgroups

Funding
Opportunities &
Initiatives

i s i o n

N


# 2024-2028 NIH-Wide Strategic Plan for Women's Health Research








Incorporating Sex & Gender Across the Research Continuum Advances Rigor, Discovery, Innovation, and **Equity** 





<sup>2</sup>The Integration of Sex and Gender Considerations into Biomedical Research: Lessons from International Funding Agencies, JCEM, 2021

# Advancing the Health of Women Through NIH Institute/Center/Office (ICO) Collaborations

#### **BIRCWH**

Building
Interdisciplinary
Research
Careers in
Women's
Health
8 ICOs\*

Mentored Career Development



#### **SCORE**

Specialized
Centers of
Research
Excellence on
Sex Differences
6 ICOs\*

Disease-Agnostic Research Centers



Administrative Supplements

Sex and Gender

22 ICOs\*

Understudied, Underrepresented, & Underreported (U3)

16 ICOs\*

Funding Program to Expand Sex & Gender Data



#### R01

Intersection of sex & gender influences on health & disease

11 ICOs\*

Sex <u>&</u> Gender Influences on Health & Disease



RFA-OD-22-028

#### R21 & R01

Understanding
Chronic Conditions
Understudied
Among Women
6 ICOs\*

Perspectives on
Advancing NIH Research
to Inform and Improve
the Health of Women
Health Conference
Report (2021)



RFA-OD-23-103 RFA-OD-23-014


## NIH Office of Autoimmune Disease Research (OADR-ORWH)

**ENHANCING NIH RESEARCH** DISEASE

- Coordinate NIH Strategic Research Plan
  - - Coordinate & foster trans-NIH collaborative research
    - Annual NIH autoimmune disease research portfolio evaluation
  - Provide *resources* to support planning, innovation, and collaboration
- Develop publicly accessible central autoimmune disease research repository



https://nap.nationalacademies.org/catalog/26554/enhancing-nihresearch-on-autoimmune-disease



## Path to Better Science and Health Equity

Improves design of clinical research and trials

Informs sex- and gender-aware.

Diagnosis and treatment

Enables individualized approaches for women and men

Fosters system-based understanding of sex and gender influences on health & disease


# Disaggregating Results by Sex Reveals Differences


Novel Findings Due to Disaggregated Analysis by Sex

**Aggregated Results** 

**Disaggregated Results** 







(McCullough, et al. Journal of Cerebral Blood Flow & Metabolism. 2005. DOI: 10.1038/sj.jcbfm.9600059)

## Sex and Gender Equity in Research (SAGER) Guidelines

SAGER Guidelines

Sex and Gender Equity in Research

Authors should use the terms sex and gender carefully to avoid confusing both terms

Where subjects can be differentiated by Bender differentiated by Bender differentiated and cultural research arty circumstances) reseasimilarly circumstances) reseasimilarly circumstances distinction distinction at this additional level of the conduction distinction

Research organisms capable and should be designed that can designed in the results,

#### **Adoption of SAGER Guidelines**





World Health Organization adopts SAGER

A significant step to bridge the gender evidence gap

#### nature

Explore content

About the journal >

Publish with us >

Subscribe

nature > editorials > article

EDITORIAL 18 May 2022

# Nature journals raise the bar on sex and gender reporting in research

Authors will be prompted to provide details on how sex and gender were considered in study design.



#### White House Women's Health Research Initiative

NOVEMBER 17, 2023

# Launch of White House Initiative on Women's Health Research

→ GPC → BRIEFING ROOM → BLOG

On November 13, President Biden announced the first-ever White House Initiative on Women's Health Research, an effort led by First Lady Jill Biden and the White House Gender Policy Council.



# Executive Order 14120: Advancing Women's Health Research and Innovation



Directs most comprehensive set of xecutive actions to expand and improve research on women's health



**MARCH 18, 2024** 

- Integrates Women's Health Across the Federal Research Portfolio | develop and strengthen research and data standards on women's health across all relevant research and funding opportunities
- Prioritizes Investments in Women's Health Research | towards funding and encourages high-impact research and innovation
- Galvanizes New Research on Women's Midlife Health | narrow research gaps more likely to occur after menopause and diseases and conditions associated with women's midlife health
- Assesses Unmet Needs to Support Women's Health Research | determine gaps in federal funding for women's health research and identify changes—whether statutory, regulatory, or budgetary—that are needed to maximally support the broad scope of women's health research.

# **Executive Order Extends Across U.S. Government Partners**

Department of Veterans Affairs





Office of Management and Budget









Presidential Budget Request:
 \$25B FY2025



Center for Medicare & Medicaid Services



National Institutes of Health










National Science Foundation





U.S. Department of Agriculture

# Transforming Women's Health Throughout the Lifespan



#### NIH-wide FY2025 \$200M Launch

- Close women's health research gaps across the lifespan
- New, interdisciplinary women's health research traversing traditional NIH Institute and Centers' missions

## Co-chaired: NIH Office and Institute Directors

- Office of Research on Women's Health (ORWH)
- National Institute on Aging (NIA)
- National Institute on Arthritis, Musculoskeletal and Skin Disease (NIAMS)
- Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
- National Institute on Drug Abuse (NIDA)
- National Heart, Lung and Blood Institute (NHLBI)



## Notice of Special Interest: Women's Health Research

First Available Due Date: May 6, 2024
Expiration Date: November 5, 2027




https://grants.nih.gov/grants/guide/notice-files/NOT-OD-24-079.html

- Aligned with White House Initiative on Women's Health Research
- Highlights NIH interest in receiving research applications focused on diseases and health conditions that:
  - predominantly affect women

     (e.g., autoimmune diseases; depressive disorders, Alzheimer's disease and Alzheimer's disease-related dementias, gender-based-violence)
  - present and progress differently in women (e.g., cardiovascular disease; HIV; reproductive aging and its implications), or
  - are female-specific

     (e.g., uterine fibroids; endometriosis; menopause)


# The NIH Women's Health Funding FRONT DOOR



# NIH Women's Health Funding Opportunities

- ORWH Opportunities and Notices
- ORWH Participating Funding
   Opportunities and Notices
- Additional NIH Women's Health Funding Opportunities
  - Highlights +45 NIH Notices of Funding Opportunities (NOFOs) advancing research for the health of women
  - Features ~200 NOFOs (Regularly Updated)

# NIH FACT SHEETS on Women's Health Research



articles/new-resource-nih-fact-sheets-on-womens-health-research-highlights-key-womens-health-issues

Highlights Department of Health and Human Services Priority Topics and Federally Supported Research

#### The Fact Sheets:

State-of-the-Science for Women's Health

- Autoimmune Diseases
- Cancer
- Cardiovascular Disease
- Dementia
- HIV

- Maternal Morbidity and Mortality
- Menopause
- Mental Health
- Substance Use
- Violence Against
   Women 37

## **CONNECT WITH ORWH**



bit.ly/ORWHpulse \*



bit.ly/ORWHevents

Women, Science, and the Impact of COVID-19

bit.ly/ORWHcovid











bit.ly/ORWHInFocus





#### **E-LEARNING**


- Sex & Gender to Improve Human
  Health
  - SABV Primer
  - SABV Primer Instructor Guide
  - Intro. to Scientific Basis of Sex- & Gender-Related Differences


bit.ly/ORWHeLearning













If not designed to address equity, research will perpetuate disparities and injustices







ncbi.nlm.nih.gov/cgr

# Revolutionizing Biological Research with the NIH Comparative Genomics Resource (CGR)


Terence Murphy, Ph.D. 7/24/2024



In what ways does your work relate to CGR-related resources?

Where do you think CGR might have the greatest impact on your goals?

What types of CGR-engagement opportunities might be most valuable?






#### Outline

- Intro to Comparative Genomics
- The Value of Research Organisms
- Problem
- CGR Solution
- CGR Impact
- What's Next



## What is comparative genomics?





# The Value of Research Organisms


Understand Basic Biological Processes & Human Disease


Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates

Joana Damas<sup>a,1</sup>, Graham M. Hughes<sup>b,1</sup>, Kathleen C. Keough<sup>c,d,1</sup>, Corrie A. Painter<sup>e,1</sup>, Nicole S. Persky<sup>f,1</sup>, Marco Corbo<sup>a</sup>, Michael Hiller<sup>g,h,i</sup>, Klaus-Peter Koepfli<sup>j</sup>, Andreas R. Pfenning<sup>k</sup>, Huabin Zhao<sup>l,m</sup>, Diane P. Genereux<sup>n</sup>, Ross Swofford<sup>n</sup>, Katherine S. Pollard<sup>d,o,p</sup>, Oliver A. Ryder<sup>q,r</sup>, Martin T. Nweeia<sup>s,t,u</sup>, Kerstin Lindblad-Toh<sup>n,v</sup>, Emma C. Teeling<sup>b</sup>, Elinor K. Karlsson<sup>n,w,x</sup>, and Harris A. Lewin<sup>a,y,z,2</sup>

https://www.pnas.org/doi/10.1073/pnas.2010146117









### Problem

Comparative genomics research faces several limitations and challenges

- Exponential data growth; variable data quality
- Siloed data and applications
- Limited number of organisms supported
- Multiple different user interfaces
- Must download data to apply tools
- Limited scalability


## Solution

#### NIH Comparative Genomics Resource (CGR)

What: CGR maximizes the impact of eukaryotic research organisms and their genomic data to biomedical research.


#### How:

- NCBI genomics toolkit
  - High-quality data
  - Tools
  - Interfaces
- Community collaboration
  - Data exchange
  - Interconnectivity





## **CGR** Impact



#### **Scientific Advancement**

Maximize impact of eukaryotic research organisms and their genomic data resources to biomedical research

#### **New Discovery Amplification**

Equal access to all eukaryotic organism data with better connections to community resources

#### **Scalable Analyses**

Support data growth with emerging big data approaches

### **New and Improved Comparative Genomics Tools**

Promote high-quality data submission, exploration, analysis, and retrieval with seamless user experiences


#### 


Serve standardized, uncontaminated, and consistently annotated eukaryotic genomic data from NCBI Archives




#### CGR Advancements

- NCBI Datasets
- BLAST
- Comparative Genome Viewer (CGV)
- Foreign Contamination Screen (FCS) Tool
- Eukaryotic Genome Annotation Pipeline (EGAPx)
- NCBI Gene
- NCBI Orthologs
- SPARCLE





**COMMAND** LINE TOOL Easy to use programmatic access to gene, genome, and virus datasets





## CGR Impact: Two Case Studies





## Finding genomic resources for organisms on NCBI

A public health biologist wants to find and contribute data for an invasive tick species

#### They need to:

- Identify available genomic data on NCBI for tick species:
  - Datasets Taxonomy
  - Datasets Genome
  - Datasets Command Line
- Improve the quality of their own data:
  - Foreign Contamination Screen
  - Genome Annotation




Haemaphysalis longicornis

Asian longhorned tick

Recently found on the East Coast!



#### Making discoveries in cancers common to humans and dogs



The following are some resources that can help in this research:



**NCBI** Gene

Multiple Sequence Alignment (MSA) Viewer



**Comparative Genome Viewer (CGV)** 

**NCBI Orthologs** 






**Genome Data Viewer (GDV)** 











### What's next for CGR?

- Ongoing resource improvements based on community feedback
  - Redesign NCBI Gene to better leverage data across species
- Public EGAPx pipeline to generate high-quality annotation for more genomes
- Multiple Comparative Genome Viewer to explore genomic differences across multiple organisms



# How Do I Learn More and Get Involved?



Reach out to us at cgr@nlm.nih.gov



Sign up for our mailing list - bit.ly/Subscribe\_CGR




Visit the CGR website ncbi.nlm.nih.gov/cgr and click the yellow Feedback button on the bottom right of the page



Look out for future meetings, workshops, webinars, surveys, small group sessions, user testing, and interviews to inform the development process





### Thank You



#### **NLM-NCBI**

Kim Pruitt

Valerie Schneider

Janet Coleman

**Anatoly Mnev** 

Anne Ketter

Katya Sukharnikov

Wratko Hlavina

Françoise Thibaud-Nissen

Nuala O'Leary

Sanjida Rangwala

Vamsi Kodali

Preye Akuiyibo

Aron Marchler-Bauer

Rana Morris

Sally Chang

#### NLM

Steve Sherry

Jodi Nurik

Diane Tuncer

NLM Board of Regents CGR Working Group

#### **NIH Oversight**

NIH CGR Steering Committee

ncbi.nlm.nih.gov/cgr cgr@nlm.nih.gov



## Thank you!

Next webinar is September 25, 2024

(August webinar is cancelled)